Low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of COVID-19 vaccines in transplanted patientstaged
Cargando...
Archivos
Fecha
2024
Autores
Arias Murillo, Yazmin Rocio
Salinas Nova, Maria Angelica
Caicedo, Tatiana
Galindo-Borda, Marisol
Meneses-Gil, Ximena
Montero, Camilo
Giron, Fernando
Pedraza, Nestor
Aroca-Martinez, Gustavo
Ospina-Martínez, Martha Lucía
Título de la revista
ISSN de la revista
Título del volumen
Editor
Elsevier
Resumen
The huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to
optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is
crucial to understand the performance of each type of available vaccine. In our study, the antibody
titer was measured, and the presence of antibodies against SARS-CoV-2 was evaluated
after 90 days of immunization; furthermore, the differences between hybrid immunity, immunity
by vaccination, and immunosuppressant type were identified. As a result, of the patients included
in this study (n = 160), 53% showed antibodies against SARS-CoV-2 90 days after the first dose
in patients who had completed the vaccination schedule. Antibody titers were higher in patients
with hybrid immunity, and the proportion of nonresponsive patients was higher among those
who received the immunosuppressant belatacept in their post-transplant regimen (P = .01). Only
15% of patients treated with this medicine seroconverted and patients vaccinated with Corona-
Vac and treated with belatacept showed no response. In conclusion, a reduced response to vaccines
against SARS-CoV-2 was identified in the transplant population, and this response varied
with the type of vaccine administered and the immunosuppressive treatment.
